Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-pTα monoclonal antibody is a biologic therapeutic agent that targets the invariant pTα (pre-T cell receptor alpha) subunit of the human pre-T cell receptor (pre-TCR). It is specifically designed to target leukemia-initiating cells (LICs) in T-cell acute lymphoblastic leukemia (T-ALL), particularly in the relapsed or refractory setting. The pre-TCR is a surface receptor essential for T-cell development and is expressed on LICs in human T-ALL but has limited expression on normal mature T cells, making it a promising biomarker for selective immunotherapy. Preclinical studies using the research clone K5G3, both as a standalone monoclonal antibody and as an antibody-drug conjugate (ADC), have demonstrated significant inhibition of leukemic cell engraftment and delayed tumor progression in mouse xenograft models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-pTα monoclonal antibody.